SCHEMBL5653423

SCHEMBL5653423

Cc1c(Br)cc2[nH]c(-c3ccc(C(=O)NCc4cccnc4)s3)nc2c1C

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 4/20 0.44
HPGD P15428 4/20 0.44
ALDH1A1 P00352 6/20 0.42
LMNA P02545 4/20 0.42
MAPK1 P28482 1/20 0.42
BLM P54132 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
KDM4E B2RXH2 2/20 0.41
HSD17B10 Q99714 1/20 0.41
HTT P42858 2/20 0.41
CASP1 P29466 1/20 0.41
MAPK10 P53779 1/20 0.41
CASP7 P55210 1/20 0.41
MAPT P10636 1/20 0.41
CHRM4 P08173 1/20 0.41
TRPA1 O75762 1/20 0.41
NPC1 O15118 1/20 0.40
TP53 P04637 1/20 0.40
POLB P06746 1/20 0.40
RAB9A P51151 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5653421 0.86 TSHR (0.44) TSHRHPGDALDH1A1LMNAMAPK1
SCHEMBL5653471 0.79 HTT (0.47) TSHRHPGDALDH1A1LMNAMAPK1
SCHEMBL5647634 0.76 ACKR3 (0.46) HPGDALDH1A1LMNAMAPK1NPSR1
SCHEMBL5651267 0.75 SORT1 (0.52) ALDH1A1LMNANPSR1HTTMAPT
SCHEMBL5648735 0.75 NPSR1 (0.43) TSHRHPGDALDH1A1LMNAMAPK1
SCHEMBL5648741 0.75 NPSR1 (0.43) TSHRHPGDALDH1A1LMNAMAPK1
SCHEMBL5651274 0.75 SORT1 (0.52) ALDH1A1LMNANPSR1KDM4EHTT
SCHEMBL5649582 0.73 MEN1 (0.55) TSHRHPGDALDH1A1LMNAMAPK1
SCHEMBL5653411 0.71 POLB (0.40) ALDH1A1MAPK1KDM4EHSD17B10TP53
SCHEMBL4919514 0.71 ESRRG (0.58) TSHRHPGDNPSR1HTTNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7220769-B2 Azolylbenzamides and analogues and their use for treating osteoporosis NIKEM RESEARCH S.R.L. (IT) 2007-05-22 US disclosed
US-20050038095-A1 Azolylbenzamides and analogues and their use for treating osteoporosis 3-V BIOSCIENCES, INC. 2005-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050038095-A1 Azolylbenzamides and analogues and their use for treating osteoporosis NR0B2, NR0B1, NCOR1 TSHR 161/4885HPGD 1586/4885ALDH1A1 2893/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.